Gayane Aghakhanyan

Dr. Gayane Aghakhanyan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in La radiologia medica
Verified
Journal Article
Open access
PDF file
ENEmanuele Neri
Emanuele Neri
GAGayane Aghakhanyan
Gayane Aghakhanyan
MZMarta Zerunian
Marta Zerunian
NGNicoletta Gandolfo
Nicoletta Gandolfo
RGRoberto Grassi
Roberto Grassi
SISIRM expert group on Artificial Intelligence
SIRM expert group on Artificial Intelligence
The term Explainable Artificial Intelligence (xAI) groups together the scientific body of knowledge developed while searching for methods to explain the inner logic behind the AI algorithm and the model inference based on knowledge-based interpretability. The xAI is now generally recognized as a core area of AI. A variety of xAI methods currently are available to researchers; nonetheless, the comprehensive classification of the xAI methods is still lacking. In addition, there is no consensus among the researchers with regards to what an explanation exactly is and which are salient properties that must be considered to make it understandable for every end-user. The SIRM introduces an xAI-white paper, which is intended to aid Radiologists, medical practitioners, and scientists in the understanding an emerging field of xAI, the black-box problem behind the success of the AI, the xAI methods to unveil the black-box into a glass-box, the role, and responsibilities of the Radiologists for appropriate use of the AI-technology. Due to the rapidly changing and evolution of AI, a definitive conclusion or solution is far away from being defined. However, one of our greatest responsibilities is to keep up with the change in a critical manner. In fact, ignoring and discrediting the advent of AI a priori will not curb its use but could result in its application without awareness. Therefore, learning and increasing our knowledge about this very important technological change will allow us to put AI at our service and at the service of the patients in a conscious way, pushing this paradigm shift as far as it will benefit us.

1 January 2024 in Radiology: Artificial Intelligence
Verified
Journal Article
Open access
GSGianfranco Di Salle
Gianfranco Di Salle
LTLorenzo Tumminello
Lorenzo Tumminello
MLMaria Elena Laino
Maria Elena Laino
SSSherif Shalaby
Sherif Shalaby
GAGayane Aghakhanyan
Gayane Aghakhanyan
ENEmanuele Neri
Emanuele Neri
Purpose To perform a systematic review and meta-analysis assessing the predictive accuracy of radiomics in the noninvasive determination of isocitrate dehydrogenase (IDH) status in grade 4 and lower-grade diffuse gliomas. Materials and Methods A systematic search was performed in the PubMed, Scopus, Embase, Web of Science, and Cochrane Library databases for relevant articles published between January 1, 2010, and July 7, 2021. Pooled sensitivity and specificity across studies were estimated. Risk of bias was evaluated using Quality Assessment of Diagnostic Accuracy Studies-2, and methods were evaluated using the radiomics quality score (RQS). Additional subgroup analyses were performed according to tumor grade, RQS, and number of sequences used (PROSPERO ID: CRD42021268958). Results Twenty-six studies that included 3280 patients were included for analysis. The pooled sensitivity and specificity of radiomics for the detection of IDH mutation were 79% (95% CI: 76, 83) and 80% (95% CI: 76, 83), respectively. Low RQS scores were found overall for the included works. Subgroup analyses showed lower false-positive rates in very low RQS studies (RQS < 6) (meta-regression, z = -1.9; P = .02) compared with adequate RQS studies. No substantial differences were found in pooled sensitivity and specificity for the pure grade 4 gliomas group compared with the all-grade gliomas group (81% and 86% vs 79% and 79%, respectively) and for studies using single versus multiple sequences (80% and 77% vs 79% and 82%, respectively). Conclusion The pooled data showed that radiomics achieved good accuracy performance in distinguishing IDH mutation status in patients with grade 4 and lower-grade diffuse gliomas. The overall methodologic quality (RQS) was low and introduced potential bias. Keywords: Neuro-Oncology, Radiomics, Integration, Application Domain, Glioblastoma, IDH Mutation, Radiomics Quality Scoring Supplemental material is available for this article. Published under a CC BY 4.0 license.

1 September 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
GAGayane Aghakhanyan
Gayane Aghakhanyan
MRMichael Rullmann
Michael Rullmann
JRJ. Rumpf
J. Rumpf
MSM. L. Schroeter
M. L. Schroeter
CSC. Scherlach
C. Scherlach
HBH. Barthel
H. Barthel

21 June 2022 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
ADAngela Dardano
Angela Dardano
GAGayane Aghakhanyan
Gayane Aghakhanyan
CMCarlo Moretto
Carlo Moretto
ACAnnamaria Ciccarone
Annamaria Ciccarone
RBRosario Bellini
Rosario Bellini
GDGiuseppe Daniele
Giuseppe Daniele

8 November 2022 in European Radiology Experimental
Verified
Journal Article
Open access
PDF file
RBRita Borgheresi
Rita Borgheresi
ABAndrea Barucci
Andrea Barucci
SCSara Colantonio
Sara Colantonio
GAGayane Aghakhanyan
Gayane Aghakhanyan
MAMassimiliano Assante
Massimiliano Assante
OGon behalf of the NAVIGATOR Consortium Group
on behalf of the NAVIGATOR Consortium Group
NAVIGATOR is an Italian regional project boosting precision medicine in oncology with the aim of making it more predictive, preventive, and personalised by advancing translational research based on quantitative imaging and integrative omics analyses. The project’s goal is to develop an open imaging biobank for the collection and preservation of a large amount of standardised imaging multimodal datasets, including computed tomography, magnetic resonance imaging, and positron emission tomography data, together with the corresponding patient-related and omics-related relevant information extracted from regional healthcare services using an adapted privacy-preserving model. The project is based on an open-source imaging biobank and an open-science oriented virtual research environment (VRE). Available integrative omics and multi-imaging data of three use cases (prostate cancer, rectal cancer, and gastric cancer) will be collected. All data confined in NAVIGATOR (i.e., standard and novel imaging biomarkers, non-imaging data, health agency data) will be used to create a digital patient model, to support the reliable prediction of the disease phenotype and risk stratification. The VRE that relies on a well-established infrastructure, called D4Science.org, will further provide a multiset infrastructure for processing the integrative omics data, extracting specific radiomic signatures, and for identification and testing of novel imaging biomarkers through big data analytics and artificial intelligence.

27 February 2023 in Frontiers in Nuclear Medicine
Verified
Journal Article
Open access
GAGayane Aghakhanyan
Gayane Aghakhanyan
GSGianfranco Di Salle
Gianfranco Di Salle
SFSalvatore Claudio Fanni
Salvatore Claudio Fanni
RFRoberto Francischello
Roberto Francischello
DCDania Cioni
Dania Cioni
ENEmanuele Neri
Emanuele Neri
The application of radiomics for non-oncologic diseases is currently emerging. Despite its relative infancy state, the evidence highlights the potential of radiomics approaches to serve as neuroimaging biomarkers in the field of the neurodegenerative brain. This systematic review presents the last progress and potential application of radiomics in the field of neurodegenerative nuclear imaging applied to positron-emission tomography (PET) and single-photon emission computed tomography (SPECT) by focusing mainly on the two most common neurodegenerative disorders, Alzheimer's (AD) and Parkinson's disease (PD). A comprehensive review of the current literature was performed using the PubMed and Web of Science databases up to November 2022. The final collection of eighteen relevant publications was grouped as AD-related and PD-related. The main efforts in the field of AD dealt with radiomics-based early diagnosis of preclinical AD and the prediction of MCI to AD conversion, meanwhile, in the setting of PD, the radiomics techniques have been used in the attempt to improve the assessment of PD diagnosis, the differential diagnosis between PD and other parkinsonism, severity assessment, and outcome prediction. Although limited evidence with relatively small cohort studies, it seems that radiomics-based analysis using nuclear medicine tools, mainly [18F]Fluorodeoxyglucose (FDG) and β-amyloid (Aβ) PET, and dopamine transporter (DAT) SPECT, can be used for computer-aided diagnoses in AD-continuum and parkinsonian disorders. Combining nuclear radiomics analysis with clinical factors and introducing a multimodality approach can significantly improve classification and prediction efficiency in neurodegenerative disorders.